On August 15, 2024, Michael Landsittel, Chief Financial Officer of Blueprint Medicines Corp (NASDAQ:BPMC), sold 4,409 shares of the company’s stock. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 67,208 shares of the company’s stock.
Blueprint Medicines Corp, based in Cambridge, Massachusetts, focuses on developing precision therapies for genomically defined diseases. The company’s approach aims to tailor medical treatments to the individual genetic profile of each patient’s disease, primarily in the areas of cancer and rare diseases.
Over the past year, Michael Landsittel has sold a total of 38,146 shares and purchased no shares. This latest transaction is part of a broader trend seen within the company. Over the past year, there were 41 insider sales and no insider purchases.
Blueprint Medicines Corp shares were trading at $95.23 on the day of the sale. The company has a market capitalization of around $6.06 billion. According to GF Value, the intrinsic value of the stock is estimated at $108.11, which suggests that the stock is slightly undervalued with a Price to GF Value ratio of 0.88.
The GF value is calculated taking into account historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio and price-free cash flow and is adjusted by GuruFocus based on the company’s past performance and expected future business results.
This insider sale may be of interest to investors who track insider behavior as an indicator of the company’s future performance and valuation adjustments.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
